Prothix focuses on protein biologics for inflammatory and coagulation disorders.
Product leads, discovered by the company or licensed in from academia, are selected based on medical need, potential markets and customer needs and mee a so-called niche-buster profile, i.e. they will be developed for niche indications to obtain clinical proof of concept, while having blockbuster promise for other indications.
Prothix will add value to these leads by executing preclinical proof of concept and early development studies. Prothix actively seeks cooperation or strategic alliances with academic groups and with companies to profile product candidates in a way that optimizes their commercial value.
All products developed by Prothix are monoclonal antibody products.
These products can be developed along a similar trajectory, which includes humanization and deimmunazation, generation of manufacturing cell-lines and development of a manufacturing process.
PRO-01PRO-01 is a novel anticoagulant drug for thromboembolic disorders. The competitive edge of this product is safety. In contrast to current anticoagulants extensive pharmacodynamic monitoring is not necessary because risk for bleeding side effects of PRO-01 is minimal.
PRO-02PRO-02 is a complement inhibitor and a novel anti-inflammatory product for antibody-mediated diseases and prevention of ischemia reperfusion damage. Several potential leads that block complement-mediated cytotoxicity of human cells sensitized with anti-HLA antibodies have been generated by Prothix.
PRO-03PRO-03 is a novel procoagulant product for bleeding disorders. PRO-03 will be first developed for hemophilia patients with inhibitors. PRO-03 has a unique mechanism of action among other procoaculant drugs such as NovoSeven, and in contrast to other procoagulant products can be given for prohpylaxis.
PRO-04PRO-04 is a novel anti-inflammatory compound that inhibits bradykinin formation. The compound has a unique mechanism of action and is developed for the treatment of different forms of angioedema.
Chief Executive Officer
Rene Verdonk, MD, MSc, MBA
Dr. Verdonk studied medicine at University of Leiden, epidemiology at Free University Amsterdam, strategic marketing at the Academy for Management of University of Groningen and business administration at the Rotterdam School of Management of Erasmus University Rotterdam. He has held key management roles in a number of biotech and pharmaceutical companies…
Scientific Officer: Prof. Cornelis Erik Hack, MD, PhD
Dr. Hack is an internationally renowned scientist and a seasoned business manager. His main research involves investigating the role of inflammation in human diseased, with particular attention to cytokines, complement, contact and coagulation systems and other mediators implicated in rheumatic and dermatologic diseased. He has strong trackrecord of conducting biochemical, preclinical…
Recent studies & articles
Eurostars grant awarded to international consortium including Abzena company, Antitope, for development of novel treatment for clotting disorders